Completed NA INTERVENTIONAL 2-arm NCT00904293

Genotype-Guided Warfarin Therapy Trial (WARFPGX)

Randomized Controlled Trial of Genotype-Guided Dosing of Warfarin Therapy

Sponsor: UNC Institute for Pharmacogenomics and Individualized Therapy

Conditions Artificial Heart Valve Atrial Fibrillation Deep Vein Thrombosis Pulmonary Embolism

Interventions Genotype-guided dose determination Non-genotype guided warfarin dosing

Updated 5 times since 2017 Last updated: May 5, 2016 Started: Aug 31, 2008 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Artificial Heart Valve and Atrial Fibrillation and is currently completed. UNC Institute for Pharmacogenomics and Individualized Therapy leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UNC Institute for Pharmacogenomics and Individualized Therapy
University of North Carolina, Chapel Hill

Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chapel Hill, United States